Semin Thromb Hemost 2024; 50(02): 284-287
DOI: 10.1055/s-0043-1771268
Commentary

Are Antiphospholipid Antibodies a Surrogate Risk Factor for Thrombosis in Sepsis?

1   Department of Haematology, Manchester University Hospitals, Manchester, United Kingdom
,
2   Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia
3   Sydney Centres for Thrombosis and Haemostasis, Westmead, NSW, Australia
4   Faculty of Science and Health, Charles Sturt University, Wagga Wagga, NSW, Australia
5   School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia
,
6   Section of Clinical Biochemistry, University of Verona, Verona, Italy
› Author Affiliations
Preview

Abstract

Antiphospholipid syndrome (APS) is a hypercoagulable state caused by antiphospholipid antibodies (aPL). APS clinically manifests with arterial or venous or microvascular thrombi and/or pregnancy complications. It is well-known that the development of aPL can be a transient phenomenon and thus the current diagnostic criterion for APS requires repeat laboratory testing several weeks apart before a definitive diagnosis is made. However, transient presence of aPL may also be pathogenic. In this article, we attempt to give historical and clinical evidence for the importance of these antibodies, even when transient, and call for further research into mechanisms by which these antibodies may promote thrombosis and pregnancy morbidities.



Publication History

Article published online:
28 July 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA